Cited by

• The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications.

  Wang X, Chen L, Wei J, Zheng H, Zhou N, Xu X, Deng X, Liu T, Zou Y. Wang X, et al. Signal Transduct Target Ther. 2025 May 23;10(1):166. doi: 10.1038/s41392-025-02220-z. Signal Transduct Target Ther. 2025. PMID: 40404619 Free PMC article. Review.
• Leveraging Health Policy Solutions to Address Obesity in Rural America.

  Ashar P, Rahim FO, Haque H, Anzaar H, Jain U, Singh S, Palakodeti S. Ashar P, et al. J Gen Intern Med. 2025 May;40(7):1538-1541. doi: 10.1007/s11606-024-09207-6. Epub 2024 Nov 18. J Gen Intern Med. 2025. PMID: 39557753
• Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review.

  Price SAL, Nankervis A. Price SAL, et al. Arch Gynecol Obstet. 2025 May;311(5):1241-1247. doi: 10.1007/s00404-024-07849-9. Epub 2025 Jan 7. Arch Gynecol Obstet. 2025. PMID: 39762582 Free PMC article. Review.
• Evaluation of unfractionated heparin dosing using an antifactor-Xa-based protocol in non-obese vs. obese patients for acute venous thromboembolism.

  Flanagan T, Sharma M, Cao UT, Wang X, Kataria V. Flanagan T, et al. J Thromb Thrombolysis. 2025 Apr;58(4):556-565. doi: 10.1007/s11239-025-03097-z. Epub 2025 Apr 5. J Thromb Thrombolysis. 2025. PMID: 40186703
• Which adiposity marker is most strongly associated with all‑cause and cause‑specific mortality? a prospective study of 158,699 Mexican adults.

  da Silva WA, Rezende LFM, Marques A, de Maio Nascimento M, Nilson E, Christofaro DGD, da Costa RF, Ferrari G. da Silva WA, et al. Int J Obes (Lond). 2025 Jul 1. doi: 10.1038/s41366-025-01827-0. Online ahead of print. Int J Obes (Lond). 2025. PMID: 40596691